Treatment (cyclophosphamide, MUC1-activated T-cells) for Refractory Plasma Cell Myeloma
Phase-Based Progress Estimates
Effectiveness
Safety
Mayo Clinic Hospital in Arizona, Phoenix, AZ
Refractory Plasma Cell Myeloma+3 More
Autologous MUC1-activated T-cells - BiologicalEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This phase I trial tests the safety, side effects and best dose of MUC1-activated T cells in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory) and is positive for expression of the MUC1 protein. T-cells are infection fighting blood cells that can kill cancer cells. MUC1-activated T-cells are made from the body's own T cells. The manufactured T-cells are made to target the MUC1 genetic marker and may help the body's immune system identify and kill cancer cells.
Eligible Conditions
- Refractory Plasma Cell Myeloma
- Recurrent Plasma Cell Myeloma
Treatment Effectiveness
Effectiveness Progress
Other trials for Refractory Plasma Cell Myeloma
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: Up to 4 years
Year 4
Overall survival
Year 4
Progression-free survival
Up to 4 years
Clinical response
Incidence of adverse events
Trial Safety
Safety Progress
Other trials for Refractory Plasma Cell Myeloma
Trial Design
1 Treatment Group
Treatment (cyclophosphamide, MUC1-activated T-cells)
1 of 1
Experimental Treatment
18 Total Participants · 1 Treatment Group
Primary Treatment: Treatment (cyclophosphamide, MUC1-activated T-cells) · No Placebo Group · Phase 1
Treatment (cyclophosphamide, MUC1-activated T-cells)Experimental Group · 2 Interventions: Autologous MUC1-activated T-cells, Cyclophosphamide · Intervention Types: Biological, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide
1995
Completed Phase 3
~4020
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 4 years
Closest Location: Mayo Clinic Hospital in Arizona · Phoenix, AZ
2022First Recorded Clinical Trial
3 TrialsResearching Refractory Plasma Cell Myeloma
2 CompletedClinical Trials
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have a serum free light chain (FLC) ≥ 10 mg/L with an abnormal free light chain ratio.
Plasma cells in bone marrow > 30% of total nucleated cells.
1 lesion that has a single diameter of ≥ 2 cm measured by CT or MRI or the CT portion of the PET/CT.
You have skin lesions in at least one area of the body.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments